Back to Search Start Over

Clinicopathological features and treatment outcome of central neurocytoma: a single institute experience.

Authors :
Mohamed, Reham
Gurusamy, Venkada M.
Orz, Yasser
Al-Yamany, Mahmoud
Ba-Faqeeh, Mohamed
Al-Obaid, Abdullah
Al-Shakweer, Wafa
Balbaid, Ali
Source :
Egyptian Journal of Neurology, Psychiatry & Neurosurgery; 9/3/2022, Vol. 58 Issue 1, p1-7, 7p
Publication Year :
2022

Abstract

Background: Despite the increased interest in publishing data on central neurocytoma, its management remains controversial. The overall incidence is approximately 0.5% of brain tumors. The reporting of institutional experience is of major need for such category of tumors to increase our knowledge and experience. In this study, we describe the clinical presentation, pathological data, and treatment outcomes of central neurocytoma. Results: Medical records of patients with neurocytoma treated in our center from July 2008 to December 2018 were retrospectively reviewed. Extra ventricular neurocytomas were excluded from analysis due to the known aggressive behavior compared to central neurocytoma. Seventeen patients treated at our center as central neurocytoma were included in the study. The frequent clinical presentation was headaches (58.8%) and paresis (35.3%). Ten patients (58.8%) developed symptoms before the age of 30 years. All patients were treated with surgical resection. Gross total resection was performed in 11 cases (64.7%) and subtotal resection was performed in 3 cases (17.7%). Four patients developed disease progression following the first excision (23.5%), for which additional resection was performed. Two patients received fractionated radiotherapy; one after the first resection due to residual disease postoperatively and the other patient following the third excision due to multiple recurrences with radiotherapy doses of 50.4 Gy and 54 Gy, respectively. The median follow-up time was 51 months (range of 14–106). The 5-year progression-free survival was 70 ± 13%. The overall survival for our cohort of patients was 100%. Conclusions: Central neurocytoma is a rare tumor of neuronal origin and surgery is the mainstay of treatment with a favorable prognosis. Adjuvant radiotherapy can be offered in patients with residual disease or multiple recurrences, especially in patients with tumors of high MIC-1 LI. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
11101083
Volume :
58
Issue :
1
Database :
Complementary Index
Journal :
Egyptian Journal of Neurology, Psychiatry & Neurosurgery
Publication Type :
Academic Journal
Accession number :
158854272
Full Text :
https://doi.org/10.1186/s41983-022-00540-3